Xtandi Unión Europea - español - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamida - neoplasmas prostáticos - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

ENZALUTAMIDA CÁPSULAS 40 mg Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

enzalutamida cápsulas 40 mg

remus pharmaceuticals pvt. ltd. india - enzalutamida 40 mg - capsulas - cada cápsula contiene: enzalutamida 40 mg

ENZALUTAMIDA 40 mg CAPSULA BLANDA Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

enzalutamida 40 mg capsula blanda

laboratorios stein s.a. costa rica - enzalutamida 40 mg - capsula blanda - cada cápsula blanda contiene: enzalutamida * 40,000 mg

ENZALUTAMIDA 40 MG CAPSULAS Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

enzalutamida 40 mg capsulas

psicofarma s.a. [ec] ecuador - enzalutamida 40 mg - capsulas de gelatina dura - cada cápsula de gelatina dura contiene: enzalutamida* 40.00 mg